Effect of recombinant human brain natriuretic peptide on myocardial enzymes and cardiac function after percutaneous coronary intervention in patients with acute myocardial infarction
Purpose: To study the effect of recombinant human brain natriuretic peptide rhBNP on myocardial enzymes and cardiac function following percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) subjects.
Methods: Patients with AMI (124 cases) subjected to PCI for 2 years were used as subjects in this investigation. Two groups of patients were used (62 patients per group). One group received rhBNP while the other group served as control. The patients consisted of 76 males and 48 females (mean age, 63.54 ± 12.31 years). The two groups of patients received 75 mg/kg body weight of clopidogrel orally and aspirin (300 mg/kg) 2 h before PCI. The peaks of creatine kinase (CK), creatine kinase MB (CKMB), and the levels of troponin I (cTnI) were assayed at pre-determined intervals with an automated biochemical analyzer, and changes in the enzyme levels were recorded. Echocardiography (ECG) parameters were also measured.
Results: Lower peaks of CK, CK-MB and levels of cTnI were seen in rhBNP-treated patients, when compared with controls (p < 0.05). Total effectiveness was markedly higher in rhBNP-treated group than in control group (p < 0.05). Moreover, myocardial infarct size was significantly lower in rhBNP treatment group than in control group (p < 0.05).
Conclusion: Treatment with rhBNP before PCI in patients with AMI increases coronary blood flow, ameliorates perfusion injury, inhibits left ventricular remodeling, reduces myocardial cell necrosis, and improves cardiac function and prognosis.
Keywords: Recombinant human brain natriuretic peptide (rhBNP), Acute myocardial infarction, percutaneous coronary intervention, Myocardial enzymes, Cardiac function
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.